Synaptogenix Inc (SNPX)

[InTheTrenches]

...overcome the limitations of traditional symptom- and sign-based phenotypic diagnoses and clinical “one-size-fits-all, magic bullet drug development” in these largely heterogeneous target populations.

Thank you for highlighting that OTHER potential drugs like AVXL's 2-73 will REQUIRE "precision medicine" and "big data analyzed by AI", and will need years to develop, while Bryostatin has a clear path to approval and acceptance because of its multi-modal effect on all aspects/symptoms of neurodegenerative diseases.

Early indications are that Bryostatin is a "one-size-fits-all, magic bullet!"

This was proven in our phase 2, when 15 out of 16 AD patients improved in their SIB score.

Why is this so important? It is accepted that only 60-80% of Alzheimer's patients are diagnosed correctly. One would expect that ~11 of the 16 patients would improve, but the "15-out-of-16" data indicates that other forms of dementia will improve with the use of Bryostatin!

This is an astounding development for Bryostatin, and if this holds up in the August/September readout, will guarantee that Bryostatin will get breakthrough development status, and may even be approved based on the confirmatory Phase 2.

We don't need no stinking precision medicine!